



JUN 29 2004

Our STN: BL 101063/5036

Merck & Company, Incorporated  
Attention: Stella I. Reed, Ph.D.  
Associate Director, Worldwide Regulatory Affairs  
Vaccines and Biologics  
Sunneytown Pike, P.O. Box 4, BLB-22  
West Point, PA 19486-0004

Dear Dr. Reed:

Your request to supplement your biologics license application for Asparaginase to include an Immunogenicity subsection in the Adverse Reactions section of the package insert has been approved.

This fulfills your commitment to revise the package insert to contain a new subsection under "ADVERSE REACTIONS" entitled "Immunogenicity" as stated in postmarketing commitment number 1 of the August 1, 2002, approval letter for STN BL 101063/5012.

Please submit all final printed labeling at the time of use and include implementation information on FDA Form 356h. Please provide a PDF-format electronic copy as well as original paper copies (ten for circulars and five for other labels).

The regulatory responsibility for review and continuing oversight for this product transferred from the Center for Biologics Evaluation and Research to the Center for Drug Evaluation and Research effective June 30, 2003. For further information about the transfer, please see <http://www.fda.gov/cder/biologics/default.htm>. Until further notice, however, all correspondence, except as provided elsewhere in this letter, should continue to be addressed to:

CBER Document Control Center  
Attn: Office of Therapeutics Research and Review  
Suite 200N (HFM-99)  
1401 Rockville Pike  
Rockville, Maryland 20852-1448

This information will be included in your biologics license application file.

Sincerely,

(b)(6)

Patricia Keegan, M.D.  
Director  
Division of Therapeutic Biological Oncology Products  
Office of Drug Evaluation VI  
Center for Drug Evaluation and Research

Enclosure:

**CONCURRENCE PAGE**

Letter Type: LETTER: Approval (AP)  
LETTER: Fulfillment of PMC (FPC)  
Summary Text: Clinical Supplmt. – Labeling Only  
REVIEW COMPLETION REQUIRED BY: RIS

**SS Data Check:**

- Place copy of Approval Ltr. with original signature concurrence page in Archival package behind the “Approval Materials” Tab after LAR (Licensing Action Recommendation).

**RIS Data Check:**

- Verify short summary – Ltr. & Submission screen should match.
- Check Letter for PMCs (if PMCs – add “PMCs – Approved With” special characteristic code.)
- Perform Review Completion Process
- Milestone: Confirm Approved Status

cc: HFM-500/K. Weiss  
HFM-573/P. Keegan  
HFM-573/P. Dinndorf  
HFM-535/A. Rosenberg  
HFM-536/B. Cherney  
HFM-541/F. Mills  
HFM-585/DARP BLA file  
HFM-110/RIMS  
HFD-013/D. Taub (with final draft PI and PPI)  
HFD-013/H. Brubaker (with final draft PI and PPI)  
HFD-240/B. Poole  
HFD-410/N. Marks (with final draft PI and PPI)  
QAS, HFM-4  
HFD-042/M. Kiester (with final draft PI and PPI)  
HFD-020/L. Burke (with final draft PI and PPI)

History: Slavin: 6-8-04: K. Townsend: 6.9.2004: 6.15.2004

File Name:

S:/Slavin/Letters/BLA/Asparaginase/101063\_5036/101063\_5036\_AP\_PMCLabeling

(b)(6)

